Drug Profile
NMI 139
Alternative Names: NO-albuminLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator NitroMed
- Developer Boston Scientific Corporation; NitroMed
- Class Albumins; Nitroso compounds
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis
Most Recent Events
- 28 Sep 1999 Preclinical development for Coronary artery restenosis in USA (Intracoronary)